Journey Medical Corp. DERM
NASDAQ · United States · Health Technology
$6.65-0.07 (-1.00%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences. Details of
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
The global papulopustular rosacea market is projected to grow steadily through 2035, driven by rising prevalence, improved diagnosis, greater patient awareness and demand for safer, non-antibiotic treatments. Advanced therapies—including topical ivermectin, azelaic acid, minocycline foam, modified-release doxycycline, biologics and microbiome-based solutions—are reshaping care. Growth across North America, Europe and Asia-Pacific is also supported by dermatology R&D, innovative drug delivery and
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.